LOGIN  |  REGISTER
Assertio
Recursion

Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners

March 14, 2022 | Last Trade: US$1.75 0.05 -2.78

Stonegate Capital Partners is hosting a webcast for Palisade Bio (NASDAQ: PALI) to discuss clinical data on LB1148, an investigational treatment of post-surgical abdominal adhesions. The virtual presentation will review the Company's data being presented at the SAGES 2022 Annual Meeting and the need for new pharmaceutical options to prevent post-surgical abdominal adhesions. The live virtual event will begin Wednesday March 16th 2022 at 8:30 am ET and be available by replay. >> Click here to register or attend.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

  • Palisade Bio to present clinical data on LB1148 on prevention of post-surgical abdominal adhesions.
  • Ronald Hurst, MD, Principal Investigator of the study and Michael Dawson, MD, to participate in virtual presentation to review data and the need for new options to
  • The webinar will be hosted by Stonegate Capital Partners on March 16th at 8:30 am ET.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7294/116651_figure1_550.jpg

 About Stonegate Capital Partners

Stonegate Capital Partners is a leading advisory firm founded in 1972. We specialize in capital markets advisory with a focus on institutional investor outreach for public and private companies. Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC) provides a full spectrum of investment banking services and equity research.

Contacts:

Erol Girgin
214.987.4121
This email address is being protected from spambots. You need JavaScript enabled to view it.

Source: Stonegate, Inc.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB